Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice.
Open Access
- 11 August 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cardiovascular Diabetology
- Vol. 15 (1), 111
- https://doi.org/10.1186/s12933-016-0431-4
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part IEuropean Heart Journal, 2013
- Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trialsBMJ, 2011
- Hypoglycemia and Cardiovascular RisksDiabetes Care, 2011
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2008
- Rosiglitazone and Cardiovascular RiskNew England Journal of Medicine, 2007
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidityEuropean Heart Journal, 2005
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998